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miR-130a and Tgfβ Content in 
Extracellular Vesicles Derived from 
the Serum of Subjects at High 
Cardiovascular Risk Predicts their 
In-Vivo Angiogenic Potential
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Alessandra trevisan3, Lorenza positello2, Pietro Rispoli3, Anna Solini  4, 
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Serum-derived extracellular vesicles (sEV) from healthy donors display in-vivo pro-angiogenic 
properties. To identify patients that may benefit from autologous sEV administration for pro-angiogenic 
purposes, sEV angiogenic capability has been evaluated in type 2 diabetic (T2DM) subjects (D), in obese 
individuals with (OD) and without (O) T2DM, and in subjects with ischemic disease (IC) (9 patients/
group). sEV display different angiogenic properties in such cluster of individuals. miRNomic profile and 
tGfβ content in sEV were evaluated. We found that miR-130a and TGFβ content correlates with sEV 
in-vitro and in-vivo angiogenic properties, particularly in T2DM patients. Ingenuity Pathway Analysis 
(IPA) identified a number of genes as among the most significant miR-130a interactors. Gain-of-function 
experiments recognized homeoboxA5 (HOXA5) as a miR-130a specific target. Finally, ROC curve 
analyses revealed that sEV ineffectiveness could be predicted (Likelihood Ratio+ (LH+) = 3.3 IC 95% 
from 2.6 to 3.9) by comparing miR-130a and TGFβ content ‘in Series’. We demonstrate that sEV from 
high cardiovascular risk patients have different angiogenic properties and that miR-130a and TGFβ sEV 
content predicts ‘true ineffective sEVs’. These results provide the rationale for the use of these assays 
to identify patients that may benefit from autologous sEV administration to boost the angiogenetic 
process.
Cardiovascular complications are relevant causes of morbidity and mortality in patients with diabetes and obe-
sity1. Recent evidence suggests that extracellular vesicles (EVs) may act as mediators of many pathophysiological 
processes2–4. EVs are small vesicles that are released from different cell types under normal and pathological 
conditions5,6. Increased levels of circulating EVs have been associated with vascular impairment and hyperco-
agulability, particularly in patients with diabetes and acute coronary syndrome, suggesting that they play a role 
in driving cardiovascular diseases7,8. Moreover, increased levels of circulating EVs, mainly from platelets and 
endothelial cells, has been proposed as a hallmark of cell dysfunction9. It has been extensively reported that EVs 
act as biological active vectors, and participate in the exchange of information between circulating and resident 
cells, including endothelial cells2,10. It has also been proposed that platelet-derived EVs play a role in the patho-
genesis of atherosclerosis11.
EVs act as biological intermediaries, and mainly do so by delivering proteins, active lipids and extracellular 
RNAs12. However, the most frequently studied EV-mediated biological processes rely on microRNA (miRNA) 
transfer. miRNAs are a class of small noncoding RNAs post-transcriptionally regulating gene expression13. miR-
NAs are present in serum/plasma and it has been proposed that their distinctive expression patterns serve as 
disease fingerprints in many clinical settings14. Moreover, it has been shown that activated platelets can transfer 
12i3T Scarl, University of Turin, Turin, Italy. 2Department of Medical Sciences, University of Turin, Turin, Italy. 
3Department of Surgical Sciences, University of Turin, Turin, Italy. 4Department of Surgical, Medical, Molecular and 
Critical Area Pathology, University of Pisa, Pisa, Italy. 5Department of Public Health and Pediatric Sciences, University 
of Turin, Turin, Italy. *email: giovanni.camussi@unito.it; mariafelice.brizzi@unito.it
open
2Scientific RepoRtS |          (2020) 10:706  | https://doi.org/10.1038/s41598-019-55783-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
functional miRNAs into vascular cells using EVs15. Similarly, EVs released from cytokine-induced inflamed ECs 
impact on both ECs and monocytes, and regulate the vascular inflammatory response via the expression of the 
intercellular adhesion molecule 1, ICAM-1, and the recruitment of inflammatory cells16. Indeed, changes in cir-
culating EV cargo have been associated with endothelial17 and smooth muscle cell dysfunction in type 2 diabetes 
(T2DM)18.
There is a growing body of evidence to suggest that EVs can act as potential therapeutic, diagnostic and 
prognostic tools19,20. We have previously developed an in-vitro test of potency to predict healthy subject-derived 
serum-EV (sEV) pro-angiogenic properties21. Since angiogenesis, particularly in the heart, peripheral arteries, 
and kidney is impaired in patients with a high cardiovascular risk profile22,23, the aims of the present study are: 
(i) to investigate in-vitro and in-vivo sEV proangiogenic capability by assessing endothelial cell proliferation/
vessel-like structure formation in-vitro and neoangiogenesis in male severe combined immunodeficiency (SCID) 
mice; (ii) to explore the possibility that a specific sEV cargo could mark effective and ineffective sEV in these 
high-risk patients making relevant their more safe and feasible autologous clinical application. Additionally, par-
ticular attention has been devoted to the analysis of sEV TGFβ content as a pre-selected target, and miRNAs by 
miRNome profiling.
Results
sEV characterisation. 9 sEV samples derived from healthy individuals (H) and 36 derived from patients 
were examined for their number and size. Patient clinical data are reported in Table 1. The size distributions 
of sEV from healthy individuals and patients did not show any significant differences (Fig. 1A,B). The aver-
age particle size was around 138 nm. A significantly higher sEV concentrations were detected in obese (O) and 
ischemic patients (IC) (Fig. 1C). The Nanoparticle Tracking Analysis (NTA) quantification values for each subject 
are reported in Supplementary Table S1. Characterisation by Guava FACS analyses revealed that sEV expressed 
CD144 and CD42b, as is typical of endothelial and platelet markers, respectively. VEGFR3+ sEVs were also found 
(Fig. S1).
Patient derived sEV pro-angiogenic activity. sEV from the different patient groups were evaluated 
for their angiogenic potential in-vitro according to our angiogenesis potency test21. As shown in Supplementary 
Table S2, we were able to distinguish effective and inefficient sEV in all patient groups. Unlike in healthy subjects, 
almost all obese/T2DM (OD) patients are characterised by the presence of sEV with proangiogenic capability. 
Individually detailed results are shown in Fig. 2A. An in-vivo angiogenic assay was performed using effective and 
ineffective sEV from the different patient groups to validate our in-vitro data in patients. As shown in Fig. 2B,C, 
we were able to demonstrate the pro-angiogenic capability of patient-derived sEV in-vivo. No statistical differ-
ences in the expression of CD144, CD42b and VEGFR3 were found when sEV with or without angiogenic poten-
tial from both healthy subjects and patients were compared.
tGfβ EV content and sEV angiogenic potential. We have previously shown that TGFβ is crucial for 
sEV-mediated angiogenic effects in healthy subjects21. ELISA was therefore performed to analyse the TGFβ con-
tent in sEV from our patients and results were compared to those of healthy subjects. As shown in Fig. 3A, TGFβ 
sEV content in obese and T2DM patients was significantly associated with their angiogenic activity. No significant 
differences in TGFβ content were detected in OD patients (Fig. 3A,B), in accordance with their functional activ-
ity. Similar results were found in IC patients. However, the TGFβ sEV content in the IC-patient group correlated 
with their angiogenic properties (Fig. 3B, Supplementary Table S3), suggesting that, unlike in OD patients, TGFβ 
cargo could be a relevant driver of their angiogenic potential. Accordingly, sEV from patient OD13 were enriched 
in TGFβ (Fig. 3A) even though they were ineffective.
sEV miRNome profile and target validation. The role of miRNAs in angiogenic processes has been 
extensively documented24,25. The possibility that differential miRNA content in sEV could also contribute to their 
functional capability was therefore investigated. A miRNome analysis (Fig. 4A and Supplementary Table S4), per-
formed using healthy effective and ineffective sEV (3 samples/each), led to the identification of 8 angio-miRNAs 
as the most differentially expressed: miR-126, miR-21, miR-296-3p, miR-210, miR-130a, miR-27a, miR-29a and 
miR-191 (Fig. 4B and Supplementary Table S5). miR-126, miR-130a, miR-27a and miR-296-3p were up-regulated, 
H D O OD IC
Age 58.0 ± 3.9 58.9 ± 6.5 49.7 ± 11.0 53.2 ± 4.1 67.2 ± 4.7
F/M 4/5 4/5 4/5 4/5 4/5
BMI 25.1 ± 0.9 25.6 ± 1.3 48.1 ± 4.9 40.9 ± 2.4 29.3 ± 6.1
HbA1c% 4.5 ± 0.2 7.9 ± 1.0 4.9 ± 0.5 7.2 ± 0.7 6.3 ± 1.7
Total Col. 163.2 ± 11.7 169.3 ± 34.5 182.3 ± 62.1 172.0 ± 44.3 123.0 ± 20.1
Smokers 5 6 6 6 5
Table 1. Healthy, Diabetic, Obese, Diabetic/Obese, and Ischemic patients’ clinical data. F/M = female/
male; BMI = Body Mass Index; Total Col = Total cholesterol (mg/dL); HbA1c = % Glycated Hemoglobin. 
H = Healthy; D = Diabetic patients; O = Obese patients; OD = Obese/Diabetic patients; IC = Ischemic patients. 
The IC group includes: patients with diabetes (IC26, IC28), obesity (IC24), and both diseases (IC25, IC27, 
IC30).
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while miR-21, miR-29a, miR-191 and miR-210 were down-regulated in sEV with proangiogenic capability 
(Fig. 4A). The expression level of differentially expressed miRNAs were evaluated in all patients and healthy sub-
jects and reported in Fig. 4B. This miRNA-list was submitted to DIANA-mirPath analysis. As shown in Fig. 4C, 
the TGFβ signalling pathway (p-value: 9.11E-08) was found to be significantly enriched. To investigate whether 
this difference was also associated with patient-sEV functional activity, their expression, evaluated using real-time 
PCR (cut-off Ct value 30), was compared to sEV angiogenic potential. We found an enrichment of miR-210 in 
almost patient-derived sEV (Fig. 4B), in accordance with results from Shalaby et al.26. However, no significant 
correlation with biological activity was detected. Interestingly, we were able to demonstrate that, unlike miR-210, 
miR-130a showed the highest level of correlation between Ct distribution and the angiogenesis potency test (3 
out of 9 in O patients, 5 out of 9 in OD and 4 out of 9 in IC patients), and in all T2DM (D) patients (Fig. 4D and 
Table 2). These results indicate that in the D group both TGFβ and miR-130a sEV content strongly correlated with 
their angiogenic properties (Figs. 3A and 4D).
DIANA-mirPath analyses were interrogated, using miR-130a, by selecting pathways involving at least 15 
genes. Once again, a significant enrichment in genes involved in the TGFβ pathway, among others, was detected 
(Fig. 4E). The network predicted by IPA for miR-130a target genes identified several genes (including: KDR, 
HOXA5, ROCK1, EPHB6) that are clearly related to the angiogenic process (Fig. 5A)27–30. Moreover, TGFβ and 
TGFBR1 genes were found among the miR-130a interactors (Fig. 5A). These results support the miR-130a con-
tribution to the sEV-mediated mechanisms of action. To validate predicted miR-130a target(s), ECs were either 
transfected with mimic-miR-130a or stimulated with sEV enriched in miR-130a and evaluated by RT-PCR and 
Western blot. Scramble miRNA and sEV carrying low miR-130a served as controls. Cell miR-130a enrichment 
was demonstrated by RT-PCR (Fig. 5B upper panel). The results of protein expression reported in Fig. 5B (lower 
panel) show that, among the predicted miR-130a targets, only homeoboxA5 (HOXA5) was downregulated in ECs 
Figure 1. Nanosight sEV characterisation. (A) Representative images of NTA analysis referred to each group 
of patients. (B) Dot-plot graph representing NTA size distribution with mean size values for healthy, obese, 
T2DM, obese/T2DM and ischemic subjects. (C) The histogram reports the number of EVs recovered from the 
serum of each group of patients. *p < 0.05 obese and ischemic patients vs healthy subjects (One-way ANOVA 
followed by Multiple Comparison Test). (n = 9 patients/group). H = Healthy subjects; D = Diabetic patients; 
O = Obese patients; OD = Obese/Diabetic patients; IC = Ischemic patients.
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Figure 2. In-vitro and in-vivo angiogenesis in response to sEVs. (A) Dot plot graph reporting the in-vitro 
proangiogenic activity of sEV recovered from each patient. The number corresponds to each patient per group 
(see Supplementary Table 3). The dotted line defines the cut-off for effective and ineffective sEV. The light 
colour corresponds to ineffective sEV per each group. (B) Representative images of vessels formed in response 
to effective and ineffective sEV. The number refers to patient sEV. (n = 3 each group except for OD. The same 
sample was used in 3 independent experiments). (C) In-vivo quantitative analysis of vessels counted in 10 
sections of Matrigel for each experimental condition. Data represent the mean value of untreated (C) (n = 3) 
and treated mice with: healthy ineffective sEV (i-sEV), healthy effective sEV (e-sEV); T2DM ineffective sEV (D 
i-sEV), T2DM effective sEV (D e-sEV); obese ineffective sEV (O i-sEV), obese effective sEV (O e-sEV); obese/
T2DM ineffective sEV (OD i-sEV), obese/T2DM effective sEV (OD e-sEV); ischemic ineffective sEV (IC i-sEV), 
ischemic effective sEV (IC e-sEV). *p < 0.05 healthy e-sEV vs. healthy i-sEV; §p < 0.05 T2DMe-sEV vs. T2DM 
i-sEV; #p < 0.05 obese e-sEV vs. obese i-sEV; °p < 0.05 obese/T2DM e-sEV vs. obese/T2DM i-sEV; +p < 0.05 
ischemic e-sEV vs. ischemic i-sEV ischemic; (One-way ANOVA followed by Multiple Comparison Test). (n = 3 
each group except for OD. The same sample was used in 3 independent experiments) ECs (red), erythrocytes 
(yellow) and Matrigel (light blue) staining in Matrigel plugs. (Original magnification: x200; scale bar: 12 µm).
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enriched in miR-130a. These results are consistent with the observation that suppression of HOXA5 attenuates 
the angiogenic process30.
miR-130a and TGFβ sEV content are valuable predictive markers for the identification of ‘true’ 
ineffective sEVs. ROC curves were interrogated to identify a simple method to discriminate sEV functional 
capability in all patient’s groups, as reported by C. Gai et al.31. In detail, ROC analyses assessed whether miR-130a 
and TGFβ sEV content have the predictive capacity to identify sEV that display proangiogenic capability from 
potency test findings. The results demonstrated that both miR-130a and TGFβ can be considered good predic-
tive measures of the ‘true ineffective sEV’ that were identified by RS, with statistically significant AUC values 
(Fig. 5B,C). Both measures displayed good sensitivity in identifying as ‘ineffective’ the ‘true ineffective sEV’ iden-
tified by RS. This was particularly evident and further underlined by the LH+ = 1.88 (IC95% from 1.49 to 2.27), 
for miR-130a (Se = 0.94 IC95% from 0.73 to 0.99) and for TGFβ (Se = 0.88 IC95% from 0.66 to 0.97). However, 
both measurements had a low specificity value (miR-130a: Sp = 0.50; TGFβ Sp = 0.64).
A good sensitivity level and increased specificity were detected (Sp = 0.75; Se = 0.82) by combining the two 
measures ‘in series’ (taking as ‘ineffective’ those sEV defined as ‘ineffective’ in both measures). The LH + value 
(Table 2) further supports these results.
Figure 3. TGFβ sEV content. (A) Data obtained per patient/group are reported. The upper curve refers to sEV 
TGFβ content, while the lower to the % of the test of potency. The dotted line defines the cut-off for effective and 
ineffective sEV. The number corresponds to each patient (n = 3 each group, except for OD. The same sample 
was used in 3 independent experiments). (B) Min to max columns represent TGFβ content in effective and 
ineffective sEVs from each group. *p < 0.05 healthy e-sEV vs. healthy i-sEV; #p < 0.05 T2DM e-sEV vs. T2DM 
i-sEV; §p < 0.05 obese e-sEV vs. obese i-sEV; (One-way ANOVA followed by Multiple Comparison Test). (n = 3, 
except for OD. The same sample was used in 3 independent experiments).
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Figure 4. miR expression and pattern analysis of sEV. (A) miRNome miRNA qPCR profiler array analysis 
on healthy effective (e-sEV) and ineffective (i-sEV). miRNAs were detected by RT-PCR. Results are reported 
as Log2−(∆Ct) (Normalized Relative Quantities) values. Dark blues circles correspond to e-sEV, while light red 
corresponds to i-sEV (n = 3/each). In red and blue, miRNAs upregulated and down regulated, respectively 
(t-test, p value < 0.05, see Supplementary Table 5). (B) miRNA validation in patient sEV. RT-PCR for miR-126, 
miR-21, miR-296-3p, miR-210, miR-130a, miR-27a, miR-29a and miR-191 was performed in all patients and 
healthy donors. Results are reported as 40-Ct. The red circle indicates patients with high miR-210 expression. 
(C) Gene Ontology analysis. Network analysis of pathways positively correlated with the miRNAs indicated 
above. Data were obtained from DIANA-mirPath analyses. The significant enrichment of the TGFβ-associated 
pathway was identified. (D) miR-130a distribution, patient-by-patient, including healthy subjects is reported 
and compared with the % of the test of potency. (E) Network analysis of pathways positively correlated with 
miR-130a. Data were obtained from DIANA-mirPath analysis. Only pathways including at least 15 genes were 
selected.
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Parameters
95% Conf. Int.
Inf Sup
Se 0.824 0.59 0.94
Sp 0.750 0.57 0.87
ACC 0.778 0.64 0.87
PPV 0.667 0.45 0.83
NPV 0.875 0.69 0.96
LH+ 3294118 2.62 3.97
LH− 0.235294 −0.81 1.28
Table 2. miR-130a and TGFβ ‘in series’ combination test. List of values obtained by combining the two 
measures ‘in series’ (taking as ‘ineffective’ those sEV defined as ‘ineffective’ in both measures). Good levels of 
sensitivity and increased specificity values were detected (Se = 0.82; Sp = 0.75). Se = Sensitivity; Sp = Specificity; 
ACC = Accuracy; PPV = Positive Predictive Value; NPV = Negative Predictive Value; LH = Likelihood Ratio.
Figure 5. miR-130a integrated interaction networks, target validation and ROC analysis. (A) Network analysis 
between miR-130a and mRNA targets. Lines represent interactions between genes and miR-130a predicted 
using the IPA Software; indirect interactions (dotted lines), direct interactions (continuous lines). Squares 
include TGFβ and TGFBR. Circles include genes involved in angiogenesis (KDR, EPHB6, ROCK1, HOXA5). 
(B) Validation of miR-130a target(s). Upper panel RT-PCR relative quantification (RQ): miR-130a relative 
amount in untreated ECs (1), in ECs transfected with miRNA Scramble (Scr) (2), with mimic-miR-130a (3), 
or treated with sEV from patients D17 (4), D18 (5), D20 (6), D1 (7), D2 (8), and D4 (9) is reported. (*p < 0.05 
samples 3, 4, 5, 6 vs. samples 1, 2, 7, 8, 9). Lower panel: KDR, ROCK1, HOXA5 and β-actin expression was 
evaluated in the above samples. sEV from patients D17, D18, D20 are enriched in miR-130a, while sEV from 
D1, D2 and D4 carry low miR-130a level. (C) ROC analysis. miR-130a and TGFβ sEV content from all patients 
and healthy subjects were analysed. Predictive capacity was evaluated for each of the two measures individually. 
A table reporting the AUC values, standard errors, p-values and threshold values is also reported.
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Discussion
The present study demonstrates that a varied cluster of chronic diseases that are characterised by high cardiovas-
cular risk are associated with different sEV angiogenic properties. We also provide evidence to show that, as in 
healthy subjects, the high TGFβ content of sEV in T2DM and obese patients predicts their proangiogenic capa-
bility (Fig. 3A). Moreover, miRnomic analyses demonstrated that miR-130a is the most relevant sEV miRNA, as 
it can predict their angiogenic properties. This is particularly true in T2DM patients (Fig. 5D). Finally, the ROC 
curve that combines data from miR-130a and TGFβ sEV content ‘in series’ demonstrated that this easy and simple 
assay is able to predict ‘true ineffective sEV.
The increased risk of cardiovascular events is a common feature in T2DM and obese patients32. Impaired 
vessel formation is still considered a relevant mechanism in abnormal vascular remodelling in these clinical 
settings33. Moreover, (micro)vessel dysfunction and vessel regression/rarefaction combined with poor neovas-
cularization contribute to pathophysiology of systemic metabolic syndrome/diabetic heart failure34. Therefore, 
boosting the neovascularisation of damaged tissues remains necessary for the improvement of patient outcomes.
Several therapeutic approaches to improve vascular remodelling in patients at high cardiovascular risk have 
been proposed35. In particular, angiogenic growth factors, and cell-based therapy exploiting bone marrow, 
peripheral blood, mesenchymal, and adipose tissues as stem/progenitor cell sources have been evaluated in clin-
ical trials to improve long-term patient outcomes36. Unfortunately, they have failed to provide real benefits37, 
meaning that novel treatment options are still required. In this paper, the angiogenic properties of sEV collected 
from patients at high risk of cardiovascular events have been thoroughly investigated, as has the role of their cargo 
in promoting vessel formation.
EVs are released by many cell types and exert their biological effects via the transfer of mRNAs, proteins, 
lipids and a wide range of non-coding RNA, such as miRNAs38. EVs, and in particular their composite cargos, 
have been consistently demonstrated to contribute to the development of cardiovascular diseases39. However, 
the therapeutic delivery of stem cell- and serum-derived EVs have been proposed as cell-free approaches for 
cardioprotection in models of cardiac ischemic injury8,20. We have recently demonstrated that the sera of healthy 
donors could contain pro-angiogenic EVs, which principally express endothelial and platelet markers. Moreover, 
we found that, when effective in promoting vessel formation in-vivo, healthy subjects-derived sEV also prevent 
skeletal-muscle damage in animals with lower limb ischemia21. This indicates that sEV angiogenic properties 
can be simply provided by the in-vivo angiogenic assay. Since angiogenesis is dysfunctional in obese, obese/
T2DM, IC, and more importantly in T2DM patients, sEV angiogenic capability was investigated as part of the 
search for novel therapeutic options. We first noticed that patients with higher cardiovascular risk have a higher 
number of circulating sEV than healthy subjects. Endothelial and platelet antigens were expressed on these sEV. 
VEGFR3-expressing sEV were also found, indicating that EVs from lymphatic vessels can be also detected in 
circulation. VEGFR3 is expressed by lymphatic vessels and drives lymphangiogenesis by binding to VEGF-C40. 
The impairment of VEGF-C–induced lymphangiogenesis via the epsin-mediated degradation of VEGFR3 has 
recently been reported in T2DM41. No differences in the number of VEGFR3 + sEV were detected. The possibility 
that the release of VEGFR3 + EVs may be a protective mechanism against VEGFR3 degradation can therefore 
be postulated.
The role of sEV in driving vascular complications in diabetes and obesity have been extensively docu-
mented42,43. Moreover, increases in the numbers of circulating EVs44–46 that display platelet47, monocyte48 and 
endothelium markers49 have been reported in individuals with cardiovascular risk factors. Fittingly, we have 
demonstrated that IC and obese individuals showed a significantly increased number of sEV. Increases in the 
number of circulating EVs that display adipose tissue markers have also been reported50. Although our data are in 
line with the study by Murakami et al.51, the possibility that adipose tissue-derived EVs may be a relevant source 
of sEV in obese patients cannot be ignored.
The role of sEV in boosting the activation of the coagulation cascade has been proposed as an explanation 
for the increased risk of cardiovascular events in obese and T2DM patients52. By contrast, whether and how sEV, 
obtained from sera of patients with cardiovascular-risk factors, display proangiogenic properties is still matter 
of study. The analysis of patient-derived sEV showed that obese/T2DM subjects had a much more active sEV 
population than healthy donors, while T2DM had the lowest activity. These data were also confirmed by the IC 
group that includes patients with diabetes (IC26, IC28), obesity (IC24), and both diseases (IC25, IC27, IC30). The 
pro-angiogenic potential of patient-derived sEV that was validated in-vivo further supported the in-vitro results. 
No significant correlation between sEV number and angiogenic activity was detected in patient’s groups. This was 
particularly true in IC patients (see Figs. 1C and 3C). This suggests that sEV angiogenic properties may depend on 
their specific cargo rather than their absolute number. The possibility that sEV from OD patients are much more 
enriched with pro-angiogenic factors should be considered.
The role of TGFβ during embryogenesis and in adult-vessel homeostasis has been highlighted by gene inacti-
vation53. We have previously shown that sEV TGFβ content was a relevant mediator of sEV proangiogenic activ-
ity21. We wondered whether sEV TGFβ content could also account for the angiogenic potential of patient-derived 
sEV. The ELISA assay demonstrated that sEV TGFβ content correlated with their angiogenic potential in only 
two patient groups: T2DM and obese. This relationship was not significant in the other two subject groups, pos-
sibly because of the small number of recruited patients. In all patient group, TGFβ sEV content correlated with 
the proangiogenic activity when it was compared to sEV angiogenic capability patient-by-patient except for the 
obese/T2DM group. Therefore, the enrichment of proangiogenic mediators, which are different from TGFβ, can 
be proposed to explain this difference. Further studies are required to validate this possibility.
However, the pro-fibrotic properties of TGFβ should not be neglected. Indeed, besides acting on ECs to induce 
the angiogenic switch, TGFβ is a crucial mediator of fibrosis in different organs54,55. This would be relevant in 
all patient groups analysed in this study, since additional kidney, liver, and heart scarring and thickening would 
eventually lead to permanent organ failure. Therefore, being such effect particularly relevant for sEV clinical 
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application, additional studies should be performed to investigate sEV pro-fibrotic effect in the heart, kidney, and 
liver before exploiting sEV to improve angiogenesis in patients at high cardiovascular risk.
Besides EV protein cargo, EV miRNA content has been reported to impact in their mechanism of action56. 
Indeed, differentially expressed angiogenic miRNAs were detected in sEVs from healthy donors that display dif-
ferent biological responses (with or without angiogenic potential). Interestingly, DIANA-mirPath analyses that 
included the indicated miRNAs (miR-126, miR-130a, miR-27a, miR-296-3p, miR-21, miR-29a, miR-191 and 
miR-210) demonstrated a significant enrichment in genes that are involved in the TGFβ-signaling pathways. High 
miR-210 levels have been proposed as a novel diagnostic biomarker for patients with cardiovascular complica-
tions26. Our finding that sEV from almost all patients (Fig. 5B) were enriched in miR-210 sustains the possibility 
that it can also be considered a biomarker for increased cardiovascular risk. This is consistent with the finding 
that an extensive spectrum of miR-210 targets that mainly regulate mitochondria metabolism, angiogenesis, DNA 
repair and cell survival have been reported49. Interestingly, we noticed that miR-130a content correlated with sEV 
angiogenic properties in all T2DM patients and in diabetic IC patients (IC26, IC28). Several genes involved in 
the angiogenic process, such as KDR, HOXA5, ROCK1 and EPHB627–30, were identified among the most relevant 
miR-130a interactors by IPA. Indeed, miR-130a overexpression or EC treatment with sEV enriched in miR-130a 
led to HOXA5 downregulation. This may be a proof of concept for its contribution to the angiogenic process. 
Moreover, the finding that TGFβ and TGFBR1 were also found among the genes that are under the control of 
miR-130a further confirms the cooperation between miR-130a and TGFβ in driving the proangiogenic activity 
of biologically active sEV.
In general, EVs are considered main paracrine and endocrine players, and their application as therapeutic 
agents would allow a safe regenerative approach. We focused on the angiogenic switch as a showcase model 
for the characterisation, efficacy testing and potential clinical translation of sEV as therapeutics. We provide 
evidence that sEV package can theoretically act on different tissues requiring new vascularization via TGFβ and 
post-transcriptional regulation of gene involved in new vessel formation. However, the therapeutic effects of 
the off-the-shelf sEV “secretome” largely depend on the complex interaction of all miRNAs and proteins taken 
together. This implies that, besides TGFβ and/or miR-130a, other proteins or genetic information transferred by 
sEV may drive a diverse range of biological processes in different target cells, dictating their fate.
Various biofluids and, more importantly, sera have been investigated as promising biomarkers for many dis-
eases, including diabetes57. This would be particularly relevant if predictions of the response to treatment could 
be obtained. We have herein identified in T2DM patients criteria to distinguish between subjects with effective 
and ineffective sEV by analysing their TGFβ and miR-130a content. We have also provided evidence that TGFβ 
and miR-130a sEV content can predict sEV ineffectiveness in all patient’s groups. In particular, combining data 
from TGFβ and miR-130a ‘in series’ has demonstrated that the test possesses good specificity (75% with IC: 95% 
vs 50%) and sensitivity (82.4% with IC: 95% vs 94%) in identifying individuals with ‘true ineffective sEV’. Our 
study therefore suggests that TGFβ and miR-130a content may be a promising non-invasive detection method for 
the recognition of individuals, especially those with T2DM, that may benefit from autologous sEV treatment. A 
larger study is required to reinforce this observation.
Of note, all obese and 5 out of 9 obese/diabetic patients displayed low sEV-miR-130a content. Low miR-
130 and high peroxisome proliferator-activated receptor gamma (PPARγ) were detected in adipose tissue from 
obese, but not lean women58. This suggests that miR-130a sEV content may predict adipose tissue perturbation, 
and thereby may be considered a specific signature of adipose tissue dysfunction in obese subjects. Finally, a 
significant negative correlation between PPARγ and circulating miR-130 level was reported in obese patients 
with colorectal cancer59. Therefore, to exploit miR-130 sEV content as a potential biomarker of colorectal cancer 
susceptibility in obese patients should be a further future challenge.
One limitation of the study is the small clinical sample, requiring external validation in cohorts from other/
multiple centres. Nevertheless, this is the first study which reports a sensitive and specific assay with which to 
evaluate sEV effectiveness in patients with different sEV angiogenic properties. Moreover, our results provides the 
rational to explore, in different cluster of patients at high cardiovascular risk, and in particular in T2DM patients, 
autologous sEV administration to improve angiogenesis. Since EV immunogenicity, isolation and scalability are 
still a matter of debate, to move from preclinical to clinical studies, autologous samples would avoid concerns on 
EV safety, isolation and storage.
Methods
Patients. Thirty-six patients at high cardiovascular risk and nine sex-matched healthy volunteers were 
included in the study. In detail, nine T2DM patients (D:n = 9), nine obese individuals (O:n = 9), nine obese 
T2DM patients (OD:n = 9) with no previous cardiovascular events, and nine ischemic patients, some of whom 
display diabetes and/or obesity while others do not, that were undergoing surgical treatment for hind limb 
ischemia in our Clinic (IC:n = 9) were herein examined. No T2DM patients received insulin treatment. No 
T2DM, obese, obese/T2DM patients were under statin treatment, whereas all IC patients received statins. Patient 
clinical data are reported in Table 1. All human experiments were performed in accordance with European 
Guidelines and policies, and were approved by the Ethical Committee of the University of Turin. Serum from 
all patients was obtained after admission to our Clinics (D, O, OD) and before surgery, for ischemic patients 
(IC). Written informed consent was obtained from all patients. Human serum from healthy donors (n = 9) was 
provided by the Blood Bank of ‘Città della Salute e della Scienza di Torino’, after informed consent and approval 
by the internal Review Board of the Blood Bank. Approval was obtained from Ethical Committee of the of ‘Città 
della Salute e della Scienza di Torino’ (protocol no: 0007814).
Study approval. Animal studies were conducted in accordance with the Italian National Institute of Health 
Guide for the Care and Use of Laboratory Animals. Approval was obtained from Ethical Committee of the Italian 
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National Institute of Health (protocol no: 490/2105-PR). Mice were housed according to the Guidelines of the 
Federation of European Laboratory Animal Science Association and the Ethical Committee of the University of 
Turin. All experiments were performed according to relevant guidelines and regulations.
Isolation of EVs from sera. Blood was obtained via venipuncture, with 9 ml serum/each participant being 
collected and stored at −80 °C. After thawing, total EVs were isolated and purified by Ultracentrifugation at 
100,000 × g for 2 h, which was preceded by centrifugation at 3000 g to remove debris. Pellets were washed once 
with PBS and centrifuged at 100,000 × g, 4 °C for 1 h. Samples were either used fresh, or thawed after being stored 
at −80°21.
Nanoparticle-tracking analyses. EVs underwent nanoparticle tracking analyses (NTA) that were per-
formed using the NanoSight LM10 system (NanoSight Ltd., Amesbury, UK), to delineate their size and profile. All 
acquisitions were carried out at a Camera level setting of 14, and three videos of 30 s duration were recorded for 
each sample. sEV were diluted (1: 1000) in 1 ml of vesicle-free physiological solution (Fresenius Kabi, Runcorn, 
UK) and analysed as previously described21.
FACS analysis. sEV FACS analyses were performed using GUAVA (Guava easyCyte™ Flow Cytometer, 
Millipore, Germany) as previously described60. The detection of nanoparticles was facilitated by the use 
of flow cytometry beads (Aldehyde/Sulfate latex 4% w/v 4 µm, Invitrogen, Germany) and APC-, PE- and 
FITC-conjugated antibodies directed to CD42b, VEGFR3 and CD144, (Dako Denmark A/S, Copenhagen, 
Denmark). FITC and PE mouse non-immune Isotypic IgG (Beckton Dickinson, Franklin Lakes, NJ) served as 
controls. EVs were incubated with each antibody, or isotype control antibody at 4 °C in 100 μl PBS containing 
0.1% bovine serum albumin, and analyzed. EVs were detected mainly below the forward scatter signal corre-
sponding to 1 mm beads (data not shown). All samples were gated on the basis of negative controls and compen-
sated appropriately prior to analyses. Population percentages/numbers were generated for gated populations from 
each experiment using Guava Incyte software (Millipore).
sEV angiogenic assay. Primary macrovascular endothelial cells (ECs) and microvascular endothelial 
cells (HMEC) were purchased from Lonza (Basel, Switzerland) and cultured as indicated in the manufacturer’s 
instructions. In-vitro tests of potency and in-vivo angiogenesis were performed as previously described21. Briefly, 
all the in-vitro study were performed administering 5 × 104 sEV/target cells. BrdU and in-vitro tubulogenesis 
assays were used to assess single sample sEV pro-angiogenic activity. EVs from of all the analysed groups were 
classified as effective or ineffective sEV (% cut-off value = 50). In-vivo angiogenesis was assessed by measuring the 
growth of blood vessels as previously described60,61. Briefly, ECs (1 × 106 cells/injection) were incubated overnight 
with sEV (5 × 1010 EVs per 1 × 106 ECs). After incubation, sEV-treated ECs were mixed with Matrigel imme-
diately before their subcutaneous injection. Male severe combined immunodeficiency (SCID) mice (6 weeks 
old/24 g) (3/each group) were then injected subcutaneously. Since the female estrus cycle could introduce unex-
pected variables, only male mice have been used in this study. An equal number of non-stimulated ECs were used 
as a negative control. The Matrigel plugs, containing wheals, were recovered on day 7 and then fixed and stained 
using the trichrome stain method. The vessel lumen area was determined as previously described21. Two different 
blind observers performed the in-vivo analysis. Animals have been used after in-vitro studies which have help to 
obtain the preliminary and key information to select the most effective therapeutic tools to be validated in-vivo. 
For animal experiments three mice have been placed in each cage. Housing of animals have been standardised to 
the following procedures: Room temperature: 22+/− 1 °C; U.R: 55+/− 10%; 12/12 light /dark cycle. Caging con-
dition: SPF animal facilities. Group housing. Environmental Enrichment. Cage size 350 cm2 minimum, 100 cm2 
per animal minimum. Animals have been anesthetised by gas anaesthesia prior to any “surgical” procedure. 
Animals have been sacrificed when they show signs of distress. We were careful in selecting a number of animals 
that was sufficient to provide statistically significant results while not unnecessary wasting them.
tGfβ ELISA assay. sEV (2.5 × 108 particles) were lysed from all healthy subjects and patients to evaluate 
TGFβ EV content (performed in triplicate). A solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay 
(ELISA, Invitrogen Multispecies TGF-β1 kit, Germany) was used, according to manufacturer’s instructions.
miR Screening. sEV miRNome was assessed via the RT-PCR of 1140 microRNA, using miRNome 
microRNA Profilers QuantiMir (SBI, System Biosciences). The kit includes assays in pre-formatted plates for 
human microRNAs with three endogenous reference RNA controls (U6, RNU43 and Hm/Ms/Rt U1) on each 
plate. We profiled the miRNome of effective (n = 3) and ineffective sEV (n = 3)21 collected from the serum of 
healthy subjects. miRNA Ct values were extrapolated for each EV sample analysed. The Ct averages from the dif-
ferent samples (n = 3) of both EV populations were normalised to endogenous controls and converted into 2−(∆Ct) 
values. miRNA validation was performed using the miScript SYBR Green PCR Kit (Qiagen, Valencia, CA, USA). 
100 ng of input RNA were reverse transcribed and the cDNA used to detect and quantify miRNAs of interest. 
Experiments were run in triplicate using 3 ng of cDNA/each reaction as described in the protocol (Qiagen). The 
following miRNAs were screened in all patient-derived EVs: miR-126, miR-21, miR-296-3p, miR-210, miR-130a, 
miR-27a, miR-29a and miR-191. qRT-PCR data were normalised using RNU6B and RNU43 as internal controls.
Pathways and miR target prediction analysis of EV content. The web-based program 
DIANA-mirPath was used for EV miRNA target prediction and biological pathway enrichment analy-
ses, as previously reported62. The algorithm microT-CDS was chosen to predict EV-derived miRNA targets 
using a default threshold (microT = 0.8). Only biological pathways with a P value < 0.01 to all known Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) pathways were considered as significantly enriched. IPA was used 
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to predict the target genes for miR-130a. We set up the miRNA Target Filter tool on IPA (Qiagen: http://www.
qiagen-bioinformatics.com/products/ingenuity-pathway-analysis/) to associate miR-130a with predicted mRNA 
targets.
miR-130a target(s) validation. Transfection of mimic-miR-130a (10 nM) was performed on ECs using 
HiPerfect Transfection method (Qiagen, Valencia, USA)63. Total RNA from untreated ECs, ECs transfected 
with mimic-miR-130a, treated with sEV with high (D17, D18, D20) or low miR-130a content (D1, D2, D4) was 
extracted using All-in-One Purification kit (Norgen, Thorold, ON Canada). miR-Scramble (Scr) was used as 
transfection reference sample. The expression of miR-130a was evaluated by RT-PCR63. miR-130a targets were 
analyzed by Western Blot analysis. Proteins were obtained using RIPA buffer, as previously described63. Anti-KDR 
(1:200, Santa Cruz), anti-ROCK1 (1:200, Abcam), and anti-HOXA5 (1:200, Abcam) antibody, together with 
anti-βactin, were used (1:200, Santa Cruz).
Statistical analysis. Data were analysed using the GraphPad Prism 6.0 Demo program. Results are 
expressed as means ± SD or ±SEM, unless otherwise reported. 1-way ANOVA, followed by Tukey’s post hoc or 
multiple comparison, Student t tests for 2-group comparison and Newman-Keuls Multiple Comparison Test 
where appropriate were used. The cut-off for statistical significance was set at p < 0.05 (*p < 0.05, **p < 0.01, 
***p < 0.001). Our data passed normality and equal variance tests. According to our previous data, the minimum 
sample size that has permitted us to detect a 40% difference between the experimental groups, with 90% power 
and a probability level of 0.05 in a two-tailed hypothesis, was n = 3 mice/group.
ROC analysis: Principal data are presented as means, standard deviations (SD), median and 95% confidence 
intervals for the two investigated groups - ‘True effective sEV’/‘True ineffective sEV’ considered as the Reference 
Standard (RS). The achievement of RS was evaluated using ROC curves31,64–67 to evaluate predictability for miR-
130a and TGFβ. sEV were classified into the following categories according to the Ct value of miR-130a and pg/
ml of TGFβ:
 1. sEV displaying a miR-130a Ct value ≥ 30 were considered to be ineffective sEV;
 2. sEV displaying TGFβ content < 1100 pg/ml were considered to be ineffective sEV.
Finally, we evaluated the ‘goodness’ of the cut-off score used for the two measures to predict ‘True ineffective 
sEV’ as defined by the RS. The predictive capacity was evaluated both for each of the two measures individually 
and by combining the two measures ‘in series’ (sEV ineffective for both measures were considered ‘ineffective 
sEV’). The analysis was based on Sensitivity (Se), Specificity (Sp), positive Likelihood ratio (LH+) (Probability of 
identifying a ‘true ineffective sEV’ as an ‘ineffective sEV’ compared to that of identifying a ‘true effective sEV’ as 
an ‘ineffective sEV’) and relative 95% Confidence Intervals values68,69.
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